SAN DIEGO and PENNINGTON, N.J., Aug.
25, 2020 /PRNewswire/ -- OncoSec Medical Incorporated
(NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing
late-stage intratumoral cancer immunotherapies, today announced
that Daniel J. O'Connor, President
and Chief Executive Officer will present at the LD 500 Virtual
Conference on Wednesday, September 2,
2020.
The presentation will begin September 2,
2020 at 10:00 a.m. eastern
time, Track 3, followed by a live Q&A session with
registered investors and other conference attendees. The OncoSec
presentation will be webcast at
https://www.webcaster4.com/Webcast/Page/2019/36144, and will be
available on the Investors section of OncoSec's website,
https://ir.oncosec.com, where it will be archived for approximately
30 days.
The virtual conference and presentations will be held via
webcast from September 1 – 4, 2020
and Mr. O'Connor will be available for virtual one-on-one meetings
throughout. To schedule a meeting, please contact Eric Lahiji at eric@ldmicro.com.
About OncoSec Medical Incorporated
OncoSec
Medical Incorporated is a late-stage biotechnology company focused
on developing cytokine-based intratumoral immunotherapies to
stimulate the body's immune system to target and attack cancer.
OncoSec's lead product candidate, TAVO™, enables the intratumoral
delivery of DNA-based interleukin-12 or IL-12, a naturally
occurring protein with immune-stimulating functions. The
technology, which employs electroporation, is designed to produce a
controlled, localized expression of IL-12 in the tumor
microenvironment, enabling the immune system to target and attack
tumors throughout the body. OncoSec has built a deep clinical
pipeline utilizing TAVO as a potential treatment for multiple
cancer indications either as a monotherapy or in combination with
leading checkpoint inhibitors. The company is currently evaluating
TAVO in combination with the anti-PD-1 checkpoint inhibitor,
KEYTRUDA® (pembrolizumab), in two KEYNOTE clinical
trials, including a pivotal trial in patients with anti-PD-1
checkpoint resistant metastatic melanoma and a phase 2 trial in
metastatic triple negative breast cancer. OncoSec is also
identifying and developing new DNA-encoded therapeutic candidates
and tumor indications for use with its novel Visceral Lesion
Applicator designed to target deep internal lesions, such as liver,
lung or pancreatic lesions. For more information, please
visit www.oncosec.com.
TAVO™ is a trademark of OncoSec Medical Incorporated.
KEYTRUDA® is a registered trademark of Merck
Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Risk Factors and Forward-Looking Statements
This
release, as well as other information provided from time to time by
the Company or its employees, may contain forward-looking
statements that involve a number of risks and uncertainties that
could cause actual results to differ materially from those
anticipated in the forward-looking statements. Forward-looking
statements provide the Company's current beliefs, expectations and
intentions regarding future events and involve risks, uncertainties
(some of which are beyond the Company's control) and assumptions.
For those statements, we claim the protection of the safe harbor
for forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995. You can identify forward-looking
statements by the fact that they do not relate strictly to
historical or current facts. These statements may include words
such as "anticipate," "believe," "could," "estimate," "expect,"
"intend," "may," "plan," "potential," "should," "will" and "would"
and similar expressions (including the negative of these
terms). Although we believe that expectations reflected in
the forward-looking statements are reasonable, we cannot guarantee
future results, levels of activity, performance or achievements.
The Company intends these forward-looking statements to speak only
at the time they are published on or as otherwise specified, and
does not undertake to update or revise these statements as more
information becomes available, except as required under federal
securities laws and the rules and regulations of the Securities
Exchange Commission ("SEC"). In particular, you should be aware
that the success and timing of our clinical trials, including
safety and efficacy of our product candidates, patient accrual,
unexpected or expected safety events, the impact of COVID-19 on the
supply of our candidates or the initiation or completion of
clinical trials and the usability of data generated from our trials
may differ and may not meet our estimated timelines. Please refer
to the risk factors and other cautionary statements provided in the
Company's Annual Report on Form 10-K for the fiscal year ended
July 31, 2019 and subsequent periodic
and current reports filed with the SEC (each of which can be found
at the SEC's website www.sec.gov), as well as other factors
described from time to time in the Company's filings with the
SEC.
Company Contact:
Kellie
Malloy
Chief Operating Officer
855.662.6732
kmalloy@oncosec.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/oncosec-to-present-at-the-ld-500-virtual-conference-on-september-2-2020-301117502.html
SOURCE OncoSec Medical Incorporated